54 research outputs found
Transmitted drug resistance and subtype patterns of viruses from reported new HIV diagnoses in Germany, 2017â2020
Background The transmission of resistant HIV variants jeopardizes the effective use of antiretrovirals for therapy and
prophylaxis. Molecular surveillance of new HIV diagnoses with a focus on prevalence and type of resistance associated
mutations and the subtype of circulating viruses is mandatory.
Method From 2017 to 2020, 11,527 new HIV diagnoses were reported in Germany to the Robert Koch Institute
(RKI). Protease (PR) and reverse-transcriptase (RT) sequences were obtained from 4559 (39.6%) cases, and PR, RT and
integrase (IN) sequences were obtained from 3097 (26.9%) cases. The sequences were analyzed with data from the
national HIV reports.
Results Among all cases in the analysis, the proportion of primary resistance was 4.3% for nucleoside reverse-
transcriptase inhibitors (NRTIs), 9.2% for non-NRTI (NNRTIs), 3.3% for protease inhibitors (PIs) and 1.4% for integrase
inhibitors (INIs). Dual-class resistance was highest for NRTIs/NNRTIs with 1.2%. There was no trend in the proportion of
viruses resistant to drug classes. Most individual key mutations associated with relevant resistance had a prevalence
below 1% including K65R (0.1%) and M184V (0.6%). A notable exception was K103NS, with a prevalence of 2.9% and a
significant increase (pTrend=0.024) during 2017â2020. In this period, diagnoses of infections with HIV-1 subtype B were
the most common at 58.7%, but its prevalence was declining (pTrend=0.049) while the frequency of minority subtypes
(each < 1%) increased (pTrend=0.007). Subtype B was highest (75.6%) in men who have sex with men (MSM) and lowest
in reported heterosexual transmissions (HETs, 22.6%).
Conclusion The percentage of primary resistance was high but at a stable level. A genotypic determination of
resistance is therefore still required before the start of therapy. The subtype diversity of circulating HIV-1 is increasing.Peer Reviewe
HIV-Studien und HIV-Projekte am Robert Koch-Institut
Neben der gesetzlich geregelten Surveillance von HIV-Neudiagnosen in Deutschland erfolgt am RKI auch die DurchfĂŒhrung verschiedener Studienprojekte, die im Epidemiologischen Bulletin 49/2019 vorgestellt werden. Das RĂŒckgrat der erweiterten HIV-Surveillance in Deutschland bilden vier Studien: das Monitoring rezenter HIV-Infektionen in Deutschland (InzSurv-HIV), die Molekulare Surveillance von HIV-Neudiagnosen (MolSurv-HIV), die HIV-1 Serokonverterstudie und die Klinische Surveillance der HIV-Erkrankung (ClinSurv-HIV). Bei InzSurv-HIV und MolSurv-HIV werden Proben von Patienten untersucht, die gerade neu diagnostiziert wurden. Bei der HIV-1 Serokonverterstudie und bei ClinSurv-HIV handelt es sich um Kohortenstudien. ErgĂ€nzend dazu wird am RKI auch das AIDS-Fallregister betrieben, in dem seit 1982 auf freiwilliger Basis anonym durch die behandelnden Ărzte berichtete AIDS-ErkrankungsfĂ€lle und -TodesfĂ€lle in Deutschland zusammengetragen und ausgewertet werden
Heritability of chronic venous disease
Varicose veins without skin changes have a prevalence of approximately 20% in Northern and Western Europe whereas advanced chronic venous insufficiency affects about 3% of the population. Genetic risk factors are thought to play an important role in the aetiology of both these chronic venous diseases (CVD). We evaluated the relative genetic and environmental impact upon CVD risk by estimating the heritability of the disease in 4,033 nuclear families, comprising 16,434 individuals from all over Germany. Upon clinical examination, patients were classified according to the CEAP guidelines as either C2 (simple varicose veins), C3 (oedema), C4 (skin changes without ulceration), C5 (healed ulceration), or C6 (active ulcers). The narrow-sense heritability (h2) of CVD equals 17.3% (standard error 2.5%, likelihood ratio test PÂ =Â 1.4Â ĂÂ 10â13). The proportion of disease risk attributable to age (at ascertainment) and sex, the two main risk factors for CVD, was estimated as 10.7% (KullbackâLeibler deviance R2). The heritability of CVD is high, thereby suggesting a notable genetic component in the aetiology of the disease. Systematic population-based searches for CVD susceptibility genes are therefore warranted
Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers : results from the Consortium of Investigators of Modifiers of BRCA1/2.
Abstract
Introduction
Previous studies have demonstrated that common breast cancer susceptibility alleles are differentially associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour.
Methods
We used genotype data on up to 11,421 BRCA1 and 7,080 BRCA2 carriers, of whom 4,310 had been affected with breast cancer and had information on either ER or PR status of the tumour, to assess the associations of 12 loci with breast cancer tumour characteristics. Associations were evaluated using a retrospective cohort approach.
Results
The results suggested stronger associations with ER-positive breast cancer than ER-negative for 11 loci in both BRCA1 and BRCA2 carriers. Among BRCA1 carriers, single nucleotide polymorphism (SNP) rs2981582 (FGFR2) exhibited the biggest difference based on ER status (per-allele hazard ratio (HR) for ER-positive = 1.35, 95% CI: 1.17 to 1.56 vs HR = 0.91, 95% CI: 0.85 to 0.98 for ER-negative, P-heterogeneity = 6.5 × 10-6). In contrast, SNP rs2046210 at 6q25.1 near ESR1 was primarily associated with ER-negative breast cancer risk for both BRCA1 and BRCA2 carriers. In BRCA2 carriers, SNPs in FGFR2, TOX3, LSP1, SLC4A7/NEK10, 5p12, 2q35, and 1p11.2 were significantly associated with ER-positive but not ER-negative disease. Similar results were observed when differentiating breast cancer cases by PR status.
Conclusions
The associations of the 12 SNPs with risk for BRCA1 and BRCA2 carriers differ by ER-positive or ER-negative breast cancer status. The apparent differences in SNP associations between BRCA1 and BRCA2 carriers, and non-carriers, may be explicable by differences in the prevalence of tumour subtypes. As more risk modifying variants are identified, incorporating these associations into breast cancer subtype-specific risk models may improve clinical management for mutation carriers
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers
Abstract
Introduction
Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2).
Methods
To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers and analysed the associations with breast cancer risk within a retrospective likelihood framework.
Results
Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 × 10-4). The association was restricted to mutations proven or predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 × 10-5, P-difference = 0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs865686, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 × 10-5) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).
Conclusions
The present findings, in combination with previously identified modifiers of risk, will ultimately lead to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2 mutation carriers
Recommended from our members
Spitzenforschung und Innovation in den Neuen LĂ€ndern - Kompetenznetzwerk fĂŒr Nanosystemintegration zu den Teilvorhaben: NEMS/MEMS-Elektronik-Integration fĂŒr energieeffiziente Sensorknoten : Abschlussbericht ; Berichtszeitraum: 01.11.2011 - 31.10.2014
[no abstract available
Recommended from our members
Abschlussbericht zum BMBF Verbundprojekt: Kompetenznetzwerk fĂŒr Nanosystemintegration : Anwendung von Nanotechnologien fĂŒr energieeffiziente Sensorsysteme ; zu den Teilvorhaben: LPB - NEMS/MEMS-Elektronik-Integration fĂŒr energieeffiziente Sensorknoten ; Berichtszeitraum: 1.11.2009 - 31.10.2012
[no abstract available
Service - das Erfolgsgeheimnis der 90er Jahre
Available from Bibliothek des Instituts fuer Weltwirtschaft, ZBW, Duesternbrook Weg 120, D-24105 Kiel C 172925 / FIZ - Fachinformationszzentrum Karlsruhe / TIB - Technische InformationsbibliothekSIGLEDEGerman
- âŠ